The overall outlook for drug pricing remains strong. Although US President Donald Trump reiterated his support for lower drug prices last Friday, little tangible action seems to be in the works.
Mylan N.V. (NASDAQ: MYL) recently put pressure on its manufacturing partner Pfizer Inc (NYSE: PFE) to resolve supply issues with EpiPen production, a life-saving product for those prone to life-threatening allergic reactions. These production slowdowns came after FDA warnings over quality control.
For more news on biotech, visit our biotechnology category.